Pharmacokinetics and cerebrospinal fluid penetration of phenylacetate and phenylbutyrate in the nonhuman primate

被引:31
作者
Berg, S
Serabe, B
Aleksic, A
Bomgaars, L
McGuffey, L
Dauser, R
Durfee, J
Nuchtern, J
Blaney, S
机构
[1] Texas Childrens Canc Ctr, Houston, TX 77030 USA
[2] Texas Childrens Hosp, Baylor Coll Med, Houston, TX 77030 USA
关键词
phenylacetate; phenylbutyrate; cerebrospinal fluid; pharmacokinetics;
D O I
10.1007/s002800000256
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: Phenylbutyrate (PB) and its metabolite phenylacetate (PA) demonstrate anticancer activity in vitro through promotion of cell differentiation, induction of apoptosis through the p21 pathway, inhibition of histone deacetylase, and in the case of PB, direct cytotoxicity. We studied the pharmacokinetics, metabolism, and cerebrospinal fluid (CSF) penetration of PA and PB after intravenous (i.v.) administration in the nonhuman primate. Methods. Three animals received 85 mg/kg PA and 130 mg/kg PB as a 30-min infusion. Blood and CSF samples were obtained at 15, 30, 35, 45, 60 or 75 min, and at 1.5, 2.5, 3.5, 5.5, 6.5, 8.5, 10.5 and 24.5 h after the start of the infusion. Plasma was separated immediately, and plasma and CSF were frozen until HPLC analysis was performed. Results. After i.v. PA administration, the plasma area under the concentration-time curve (AUC) of PA (median +/- SD) was 82 +/- 16 mg/ml.min, the CSF AUC was 24 +/- 7 mg/ml.min, clearance (C1) was 1 +/- 0.3 ml/min per kg, and the AUC(CSF):AUC(plasma) ratio was 28 +/- 19%. After i.v. PB administration, the plasma PB AUC was 19 +/- 3 mg/ ml min, the CSF PB AUC was 8 +/- 11 mg/ml.min, the PB C1 was 7 +/- 1 ml/min per kg, and the AUC(CSF):AUC(plasma) ratio was 41 +/- 47%. The PA plasma AUC after i.v. PB administration was 50 +/- 9 mg/ml.min, the CSF AUC was 31 +/- 24 mg/ml.min, and the AUC(CSF):AUC(plasma) ratio was 53 +/- 46%. Conclusions. These data indicate that PA and PB penetrate well into the CSF after i.v. administration. There may be an advantage to administration of PB over PA, since the administration of PB results in significant exposure to both active compounds. Clinical trials to evaluate the activity of PA and PB in pediatric central nervous system tumors are in progress.
引用
收藏
页码:385 / 390
页数:6
相关论文
共 30 条
[1]  
BLANEY SM, 1993, CANCER RES, V53, P725
[2]   TREATMENT OF EPISODIC HYPERAMMONEMIA IN CHILDREN WITH INBORN-ERRORS OF UREA SYNTHESIS [J].
BRUSILOW, SW ;
DANNEY, M ;
WABER, LJ ;
BATSHAW, M ;
BURTON, B ;
LEVITSKY, L ;
ROTH, K ;
MCKEETHREN, C ;
WARD, J .
NEW ENGLAND JOURNAL OF MEDICINE, 1984, 310 (25) :1630-1634
[3]   Phase II study of phenylacetate in patients with recurrent malignant glioma: A North American brain tumor consortium report [J].
Chang, SM ;
Kuhn, JG ;
Robins, HI ;
Schold, SC ;
Spence, AM ;
Berger, MS ;
Mehta, MP ;
Bozik, ME ;
Pollack, I ;
Schiff, D ;
Gilbert, M ;
Rankin, C ;
Prados, MD .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (03) :984-990
[4]  
DONEHOWER RC, 1986, CANCER TREAT REP, V70, P1059
[5]   Inhibitory effects of phenylbutyrate on the proliferation, morphology, migration and invasiveness of malignant glioma cells [J].
Engelhard, HH ;
Homer, RJ ;
Duncan, HA ;
Rozental, J .
JOURNAL OF NEURO-ONCOLOGY, 1998, 37 (02) :97-108
[6]   CONJUGATION OF PHENYLACETIC ACID IN MAN, SUB-HUMAN PRIMATES AND SOME NON-PRIMATE SPECIES [J].
JAMES, MO ;
WILLIAMS, RT ;
SMITH, RL ;
REIDENBE.M .
PROCEEDINGS OF THE ROYAL SOCIETY SERIES B-BIOLOGICAL SCIENCES, 1972, 182 (1066) :25-+
[7]   MLAB - MATHEMATICAL-MODELING TOOL [J].
KNOTT, GD .
COMPUTER PROGRAMS IN BIOMEDICINE, 1979, 10 (03) :271-280
[8]  
Lau C. C., 1998, Proceedings of the American Association for Cancer Research Annual Meeting, V39, P108
[9]  
LEA MA, 1995, ANTICANCER RES, V15, P879
[10]   DIFFERENTIATION OF CULTURED HUMAN-MELANOMA CELLS INDUCED BY THE AROMATIC FATTY-ACIDS PHENYLACETATE AND PHENYLBUTYRATE [J].
LIU, L ;
SHACK, S ;
STETLERSTEVENSON, WG ;
HUDGINS, WR ;
SAMID, D .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1994, 103 (03) :335-340